Let's be clear about what's happening here: entrepreneurs are building businesses around products that exist in a regulatory twilight zone. Not illegal, not approved, not quite supplements, not quite drugs. It's the kind of ambiguity that Silicon Valley loves — move fast, sell peptides, figure out the liability later.

On one hand, there's a libertarian case to be made. Adults should have the freedom to decide what goes into their own bodies, and the FDA's approval process is notoriously slow and expensive. If someone wants to experiment with BPC-157 or GHK-Cu after doing their own research, that's arguably their right. The paternalistic instinct to ban everything unapproved isn't exactly a track record of success.

But here's where it gets uncomfortable: these aren't informed biohackers mixing compounds in their garages. These are startups with marketing budgets, influencer partnerships, and slick branding designed to make gray-market compounds feel as safe as ordering from Amazon. There's a meaningful difference between defending someone's right to make their own health choices and building a venture-backed business model that depends on consumers not fully understanding the risks.

The real failure, as usual, is regulatory. The FDA could create clearer pathways for peptide research and consumer access. Instead, we get the worst of both worlds — a lumbering bureaucracy that's too slow to approve promising compounds and too toothless to crack down on sketchy ones. That vacuum gets filled by startups whose primary innovation isn't science but regulatory arbitrage.

If San Francisco's peptide boom produces genuinely useful therapies, great. But betting your Series A on the FDA staying asleep at the wheel isn't a business strategy — it's a prayer.